Regulatory T cells in solid organ transplantation

Clinical & Translational Immunology

Ye Htun Oo¹  Muhammad Atif²  Makoto Miyara²  Guy Gorochov²  Filomena Conti³ 

[1] Centre for Liver and Gastro Research NIHR Birmingham Biomedical Research Centre University of Birmingham Birmingham UK;Sorbonne Université Inserm U1135 Centre d'Immunologie et des Maladies Infectieuses (CIMI‐Paris) Hôpital Pitié‐Salpêtrière AP‐HP Paris France;Unité de Transplantation Hépatique Hôpital Pitié‐Salpêtrière AP‐HP Paris France;

关键词: clinical trial;    FOXP3;    regulatory T cells;    safety;    transplant;    Treg;   

DOI  :  10.1002/cti2.1099

来源: DOAJ

【 摘 要 】

Abstract The induction of graft tolerance remains the holy grail of transplantation. This is important as chronic allograft dysfunction and the side effects of immunosuppression regimens place a major burden on the lives of transplant patients and their healthcare systems. This has mandated the need to understand the immunobiology of graft rejection and identify novel therapeutics. Regulatory T (Treg) cells play an important role in modulating pro‐inflammatory microenvironments and maintaining tissue homeostasis. However, there are fundamental unanswered questions regarding Treg cell immunobiology. These cells are a heterogeneous entity with functionally diverse roles. Moreover, the adoption of novel deeper immunophenotyping and genomic sequencing technologies has identified this phenotype and function to be more complex than expected. Hence, a comprehensive understanding of Treg cell heterogeneity is needed to safely and effectively exploit their therapeutic potential. From a clinical perspective, the recent decade has seen different clinical teams commence and complete first‐in‐man clinical trials utilising Treg cells as an adoptive cellular therapy. In this review, we discuss these trials from a translational perspective with an important focus on safety. Finally, we identify crucial knowledge gaps for future study.

【 授权许可】

Unknown